Geode Capital Management
PYXS icon

Geode Capital Management’s Pyxis Oncology PYXS Stock Holding History

Geode Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Sell
591,849
-6,272
-1% -$12K ﹤0.01% 3217
2026
Q1 		$874K Buy
598,121
+20,910
+4% +$31.5K ﹤0.01% 3397
2025
Q4 		$664K Buy
577,211
+32,703
+6% +$115K ﹤0.01% 3501
2025
Q3 		$1.21M Buy
544,508
+33,545
+7% +$48.3K ﹤0.01% 3323
2025
Q2 		$562K Sell
510,963
-598,135
-54% -$674K ﹤0.01% 3516
2025
Q1 		$1.09M Buy
1,109,098
+26,649
+2% +$35.6K ﹤0.01% 3279
2024
Q4 		$1.69M Sell
1,082,449
-2,278
-0.2% -$6.57K ﹤0.01% 3194
2024
Q3 		$3.98M Buy
1,084,727
+57,016
+6% +$200K ﹤0.01% 2883
2024
Q2 		$3.4M Buy
1,027,711
+687,590
+202% +$2.89M ﹤0.01% 2927
2024
Q1 		$1.45M Buy
340,121
+31,880
+10% +$134K ﹤0.01% 3234
2023
Q4 		$555K Buy
308,241
+19,942
+7% +$34.2K ﹤0.01% 3567
2023
Q3 		$574K Buy
288,299
+45,512
+19% +$105K ﹤0.01% 3546
2023
Q2 		$622K Buy
242,787
+3,436
+1% +$10.9K ﹤0.01% 3559
2023
Q1 		$960K Buy
239,351
+35,417
+17% +$70.7K ﹤0.01% 3367
2022
Q4 		$273K Buy
203,934
+15,113
+8% +$22.7K ﹤0.01% 3935
2022
Q3 		$371K Buy
188,821
+78,974
+72% +$206K ﹤0.01% 3887
2022
Q2 		$261K Sell
109,847
-84,730
-44% -$226K ﹤0.01% 4109
2022
Q1 		$786K Buy
194,577
+13,105
+7% +$95.8K ﹤0.01% 3720
2021
Q4 		$1.99M Buy
+181,472
New +$2.08M ﹤0.01% 3361

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Geode Capital Management's PYXS Position: Q2 2026 in Review

Geode Capital Management reduced its Pyxis Oncology (PYXS) stake by 1% in Q2 2026, selling an estimated $12K and leaving 591,849 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

Geode Capital Management first reported a position in PYXS in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.98M in Q3 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Geode Capital Management held 591,849 shares of Pyxis Oncology worth $1.78M as of Q2 2026.
  • Geode Capital Management sold 6,272 Pyxis Oncology shares in Q2 2026, an estimated $12K.
  • Pyxis Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3217 holding.
  • Geode Capital Management first reported a position in Pyxis Oncology in Q4 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Pyxis Oncology position peaked at $3.98M in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.